

Speaker Disclosure of Relevant Financial Relationships

Relevant financial relationships for all planners, reviewers, and faculty have been mitigated.

The **ANCO** planners and managers have nothing to disclose. The **i3 Health** planners and managers have nothing to disclose.

Hemali Batra-Sharma, MD - Disclosed the following financial relationships; **Consultant:** Targeted Oncology roundtables (2023, 2022); **Other Financial or Material Support (royalties, patents, etc.):** Honoraria from Targeted Oncology, OncoLive, Curio Science, Doximity; **Stock/Shareholder (excluding diversified mutual funds):** Tempus.

Jeffery Bien, MD - Disclosed no relevant financial relationships with commercial interests.

Chris Chen, MD - Disclosed the following financial relationships; **Advisory Board or Panel:** D3 Bio; **Consultant:** Boxer Capital, Guidepoint Global, Mubadala Capital, Johnson & Johnson; **Grants/Research Support2:** ADC Therapeutics, Gilead Sciences, Kinnate Biopharma, Mersana, ORIC Pharmaceuticals, Palleon Pharmaceuticals, Pionyr Therapeutics, Rain Oncology, Seagen, Takeda, Genentech-Roche, D3 Bio, Revolution Medicines, Tango Therapeutics, Bolt Biotherapeutics.

Adil Daud, MD - Disclosed the following financial relationships; **Advisory Board or Panel:** Genoptix; GlaxoSmithKline; Caris, Eisai, GLG; **Consultant:** Genoptix; GlaxoSmithKline; Oncosec; Caris, Eisai, GLG; **Grants/Research Support2:** Bristol-Myers Squibb; Checkmate Pharmaceuticals; Checkmate Pharmaceuticals; Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Merck/Schering; **Stock/Shareholder (excluding diversified mutual funds):** Neuvogen; Trex bio.

Sheila Firoozan, MD - Disclosed no relevant financial relationships with commercial interests.

Matthew Gubens, MD, MS, FASCO - Disclosed the following financial relationships; **Advisory Board or Panel:** AstraZeneca, Atreca, Bicycle, BMS, Cardinal Health, Catalyst, Genentech/Roche, Invitae, Johnson and Johnson, Merus, Natera, Nuvalent, OncoHost, Regeneron; **Consultant:** DSMB for Samsung Bioepis; **Grants/Research Support2:** To institution as site PI) Amgen, Johnson and Johnson, Merck, Trizell.

Vadim Koshkin, MD - Disclosed the following financial relationships; **Research Support (Institution):** Curium, Eli Lilly, Endocyte/Novartis, Gilead, Merck, Nektar, Seagen/Pfizer and Taiho; **Research Funding:** Eli Lilly, Astellas/Merck, Prostate Cancer Foundation; **Consulting or Advisory Role:** Astellas, AstraZeneca, Bicycle Therapeutics, BMS, Janssen, Loxo Oncology, MSD, Pfizer/Seagen, Roche, Tempus.

Zach Koontz, MD - Disclosed the following financial relationships; **Stock/Shareholder (excluding diversified mutual funds)**: Merck <\$50k.

E. Clair McClung, MD - Disclosed no relevant financial relationships with commercial interests.

Shiruyeh Schokrpur, MD, PhD - Disclosed the following financial relationships; **Consultant**: OncoHost, Navya.

Tilak Sundaresan, MD - Disclosed no relevant financial relationships with commercial interests.